63.38
+5.93%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About TG Therapeutics
From its filings with the US Securities and Exchange Commission
TG Therapeutics is based in New York, New York and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker TGTX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $616.3m and net income of $447.2m. At that date it held total assets of $1.06bn and shareholders' equity of $648.0m.
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. We also actively evaluate complementary products, technologies and companies for in-licensing, partnership, acquisition and/or investment opportunities.
Launched, Next In MS™, a platform designed to foster honest, real-world conversations about life with MS—featuring unfiltered dialogue, including discussions with Christina Applegate—and to support people living with MS in continuing those conversations with family, friends, and healthcare professionals on their own terms.
Quoted from its 10-K, filed 27 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 14 Dec 1995
- Employees
- 399
- Website
- tgtherapeutics.com ↗
- Head office
- 2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY, 10014
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Michael WeissChairman of the Board, President, Chief Executive Officer, since 2011$18.8m
- Mr. Sean PowerChief Financial Officer, Treasurer, Corporate Secretary$2.3m
- Mr. Laurence CharneyLead Independent Director$510,633
- Dr. Yann EchelardIndependent Director$468,133
- Mr. Kenneth HobermanIndependent Director$470,633
- Mr. Daniel HumeIndependent Director$468,133
- Dr. Sagar LonialIndependent Director$465,633
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 26
- Environment
- 4
- Social
- 32
- Governance
- 42
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong Pipeline: TG Therapeutics Inc maintains a robust pipeline of potential therapeutics, demonstrating their dedication to research and development.
- Innovative Approach: The company adopts innovative approaches to develop novel therapies, contributing to their competitive advantage in the pharmaceutical industry.
- Experienced Team: TG Therapeutics Inc is supported by a highly skilled and experienced management team, allowing for effective decision-making and strategic planning.
Weaknesses
- Dependence on Key Products: The company's success heavily relies on the performance of a few key products in their portfolio. Any setbacks or regulatory issues concerning these products could negatively impact their financial stability.
- Limited Market Presence: TG Therapeutics Inc may face challenges in establishing a strong market presence, as they operate in a highly competitive industry dominated by larger pharmaceutical companies.
- Financial Constraints: The company's financial resources may limit their ability to fully explore and develop certain research opportunities, potentially hindering their growth and innovation.
Opportunities
- Growing Demand for Innovative Therapies: The increasing demand for groundbreaking therapies presents TG Therapeutics Inc with an opportunity to capitalize on their innovative drug candidates and gain a significant market share.
- Strategic Partnerships: Collaborating with established pharmaceutical companies or research institutions can provide TG Therapeutics Inc with additional resources, expertise, and opportunities for expansion.
- Mergers and Acquisitions: The company could explore potential mergers or acquisitions to enhance their product portfolio, accelerate development timelines, or access new markets.
Threats
- Stringent Regulatory Environment: The pharmaceutical industry is subject to strict regulations, which may delay or impede TG Therapeutics Inc's product development process, leading to increased costs and potential market entry barriers.
- Patent Expirations: The expiration of key patents for competitor products may increase market competition and affect the pricing and demand for TG Therapeutics Inc's offerings.
- Clinical Trial Risks: The company faces the inherent risks associated with clinical trials, such as unexpected adverse events or failure to demonstrate efficacy, which could negatively impact their reputation and financial performance.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.